Drug resistance-associated mutations at 12 months of ART.

<p><b>Legend </b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072680#pone-0072680-t004" target="_blank"><b>table 4</b>:</a> PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; HIVDR: HIV Drug Resistance.</p

Socio-demographic and medical data of the study population.

<p><b>Legend </b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072680#pone-0072680-t001" target="_blank"><b>table 1:</b></a> ART: Antiretroviral therapy; HAART: Highly Active Antiretroviral therapy;</p><p>PMTCT: prevention of mother-to-child transmission; IQR: Interquartile range.</p

HIV drug resistance at enrollment on ART.

<p><b>Legend </b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072680#pone-0072680-t002" target="_blank"><b>table 2</b>:</a> PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; HAART: highly active antiretroviral therapy; VL: viral load; LTFU: lost to follow-up; NVP: nevirapine; 3TC: lamivudine; AZT: zidovudine; d4T: stavudine; EFV: efavirenz.</p

Virologic outcome at the study endpoint (M12).

<p><u>Legend</u>: NA: not applicable.</p